Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

138.10USD
21 Mar 2019
Change (% chg)

$0.81 (+0.59%)
Prev Close
$137.29
Open
$137.00
Day's High
$138.78
Day's Low
$136.97
Volume
2,012,752
Avg. Vol
2,735,795
52-wk High
$148.97
52-wk Low
$118.62

Latest Key Developments (Source: Significant Developments)

Oxfam America Says Urges J&J Shareholders To Vote For Resolution At Annual Meeting Of J&J
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Johnson & Johnson ::OXFAM AMERICA SAYS URGES J&J SHAREHOLDERS TO VOTE FOR RESOLUTION AT THE ANNUAL MEETING OF JOHNSON AND JOHNSON - SEC FILING.OXFAM AMERICA - RESOLUTION ASKS J&J TO REPORT EXTENT TO WHICH RISKS RELATED TO PUBLIC CONCERN OVER DRUG PRICING ARE INTEGRATED INTO SENIOR EXECUTIVES' COMPENSATION ARRANGEMENTS.  Full Article

New Phase 3 Stelara (Ustekinumab) Data Show Positive Results As Maintenance Therapy In Adults With Moderate To Severe Ulcerative Colitis
Monday, 11 Mar 2019 

March 11 (Reuters) - Johnson & Johnson ::NEW PHASE 3 STELARA (USTEKINUMAB) DATA SHOW POSITIVE RESULTS AS MAINTENANCE THERAPY IN ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS.JANSSEN - SIGNIFICANTLY GREATER PROPORTION OF ADULT PATIENTS WITH MODERATE TO SEVERE UC GETTING STELARA SC MAINTENANCE THERAPY WERE IN CLINICAL REMISSION AT 1 YEAR.  Full Article

Imbruvica (Ibrutinib) Combination Regimen To Treat Waldenström's Macroglobulinemia Approved Through Health Canada Priority Review
Friday, 8 Mar 2019 

March 8 (Reuters) - Johnson & Johnson ::IMBRUVICA (IBRUTINIB) COMBINATION REGIMEN TO TREAT WALDENSTRÖM'S MACROGLOBULINEMIA APPROVED THROUGH HEALTH CANADA PRIORITY REVIEW.JANSSEN SAYS APPROVAL EXPANDS INDICATION OF IMBRUVICA IN WM.  Full Article

Janssen Announces U.S. FDA Approval Of Spravato CII Nasal Spray For Adults With Treatment-Resistant Depression
Wednesday, 6 Mar 2019 

March 5 (Reuters) - Janssen: :JANSSEN ANNOUNCES U.S. FDA APPROVAL OF SPRAVATO™ (ESKETAMINE) CIII NASAL SPRAY FOR ADULTS WITH TREATMENT-RESISTANT DEPRESSION (TRD) WHO HAVE CYCLED THROUGH MULTIPLE TREATMENTS WITHOUT RELIEF.JANSSEN - ANNOUNCED U.S. FDA HAS APPROVED SPRAVATO (ESKETAMINE) CIII NASAL SPRAY FOR ADULTS WITH TREATMENT-RESISTANT DEPRESSION.  Full Article

Johnson & Johnson Reports 8.7 Percent Passive Stake In Meiragtx Holdings- SEC Filing
Monday, 4 Mar 2019 

March 4 (Reuters) - Johnson & Johnson ::JOHNSON & JOHNSON REPORTS 8.7 PERCENT PASSIVE STAKE IN MEIRAGTX HOLDINGS PLC AS OF MARCH 1, 2019 - SEC FILING.  Full Article

Adorx Announces Collaboration With Johnson & Johnson Innovation
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Adorx Therapeutics::ADORX THERAPEUTICS ANNOUNCES COLLABORATION WITH JOHNSON & JOHNSON INNOVATION TO DEVELOP NOVEL LUNG CANCER THERAPEUTICS.ADORX THERAPEUTICS - FINANCIAL TERMS OF COLLABORATION WITH JOHNSON & JOHNSON WERE NOT DISCLOSED.ADORX THERAPEUTICS - UNDER AGREEMENT, CO GRANTED EXCLUSIVE OPTION TO RESEARCH, DEVELOP, COMMERCIALISE NOVEL ANTAGONISTS WITHIN ADORX PORTFOLIO.ADORX THERAPEUTICS - UNDER TERMS OF AGREEMENT GROUPS WILL COLLABORATE ON DRUG DISCOVERY AND PRECLINICAL DEVELOPMENT ACTIVITIES.  Full Article

Competition Bureau Completes Investigation Into Alleged Abuse Of Dominance By Janssen Inc
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Johnson & Johnson ::COMPETITION BUREAU COMPLETES INVESTIGATION INTO ALLEGED ABUSE OF DOMINANCE BY JANSSEN INC..COMPETITION BUREAU - CONCLUDED THERE IS INSUFFICIENT EVIDENCE TO SHOW JANSSEN'S CONDUCT SUBSTANTIALLY LESSENED/PREVENTED COMPETITION IN RELEVANT MARKET.  Full Article

Biomx Raises $32 Million In Series B Financing
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - BiomX Ltd::BIOMX RAISES $32 MILLION IN SERIES B FINANCING.BIOMX - FINANCING WAS LED BY EXISTING INVESTORS ORBIMED, JOHNSON & JOHNSON INNOVATION - JJDC, INC., TAKEDA VENTURES & OTHERS.BIOMX-FINANCING PROCEEDS TO BE USED PRIMARILY TO ADVANCE CO'S LEADING DRUG CANDIDATES FOR TREATMENT OF ACNE & INFLAMMATORY BOWEL DISEASE TO CLINIC.  Full Article

Johnson & Johnson - Prelim Results From Phase 2 Study In Adults With Metastatic Castration-Resistant Prostate Cancer And DNA-Repair Pathway Defects
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Johnson & Johnson ::JANSSEN ANNOUNCES PRELIMINARY RESULTS FROM PHASE 2 GALAHAD STUDY IN ADULTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND DNA-REPAIR PATHWAY DEFECTS (DRD).JANSSEN - DATA SHOWED NIRAPARIB DEMONSTRATED ORR OF ABOUT 40 PERCENT IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, DNA-REPAIR PATHWAY DEFECTS.  Full Article

U.S. FDA Approves Darzalex Split-Dosing Regimen
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - Johnson & Johnson ::U.S. FDA APPROVES DARZALEX® (DARATUMUMAB) SPLIT-DOSING REGIMEN.JANSSEN PHARMACEUTICAL - U.S. FDA APPROVES DARZALEX® (DARATUMUMAB) SPLIT-DOSING REGIMEN.  Full Article

UPDATE 1-Novartis says listing of Alcon eye care business expected on April 9

ZURICH, March 22 Shares in Alcon, the eye care business being spun-off by Novartis, are expected to start trading on April 9 on the Swiss market and the New York Stock Exchange, the Swiss pharmaceuticals company said on Friday.